Medication persistence in the treatment of HIV infection: a review of the literature and implications for future clinical care and research
Remedicalizing an epidemic: from HIV treatment as prevention to HIV treatment is prevention
Enhancing effects of adjuvanted 2009 pandemic H1N1 influenza A vaccine on memory B-cell responses in HIV-infected individuals
Effect of highly active antiretroviral therapy on biomarkers of B-lymphocyte activation and inflammation
Monoboosted lopinavir/ritonavir as simplified second-line maintenance therapy in virologically suppressed children
Low level of the K103N HIV-1 above a threshold is associated with virological failure in treatment-naive individuals undergoing efavirenz-containing therapy
A comparison of neuropsychiatric adverse events during 12 weeks of treatment with etravirine and efavirenz in a treatment-naive, HIV-1-infected population
Higher efficacy of nevirapine than efavirenz to achieve HIV-1 plasma viral load below 1 copy/ml
Younger age at HAART initiation is associated with more rapid growth reconstitution
Effects of central nervous system antiretroviral penetration on cognitive functioning in the ALLRT cohort
Boosted protease inhibitors and the electrocardiographic measures of QT and PR durations
Tracking the biological risk of coronary artery disease in HIV-infected individuals: the case of circulating endothelial progenitor cells
SENSE makes us rethink the second-generation nonnucleoside reverse transcriptase inhibitor etravirine's place in HIV-1 treatment
Protective interleukin-28B genotype affects hepatitis C virus clearance, but does not contribute to HIV-1 control in a cohort of African–American elite controllers/suppressors
Paradoxically elevated efavirenz concentrations in HIV/tuberculosis-coinfected patients with CYP2B6 516TT genotype on rifampin-containing antituberculous therapy
The imperative to respond with appropriate and timely interventions to mass rape in conflict-affected areas
A comparison of patients' attitudes to antiretroviral toxicities between the UK and Uganda
Inappropriate claim of ‘failure of ritonavir-boosted lopinavir monotherapy in HIV’ in the Monotherapy Switzerland/Thailand (MOST) trial
HIV-1 trans-activator protein dysregulates IFN-γ signaling and contributes to the suppression of autophagy induction
Virologic and immunologic response to HAART, by age and regimen class: Erratum